Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Data from the first studies to directly compare two different adjuvanted formulations of GlaxoSmithKline's candidate cervical cancer vaccine Cervarix have revealed that the immune response induced by the vaccine formulated with the company's proprietary AS04 adjuvant system was consistently stronger and more sustained than that observed with a conventional adjuvant formulation.
Subscribe to our email newsletter
Additionally, Olsen, who is the company’s current chief operating officer, will continue to serve in that capacity for both divisions while the board of directors engages in a search for Hernandez’ successor.
IBI is engaged in developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets.